Our data may suggest the development of new heterobivalent o multitargeting agonist pharmacophores acting on Y1R–GALR2 heterocomplexes in the ventral hippocampus for the novel therapy of MDD or depressive‐affecting diseases. The gene discussed is GALR2; the disease is major depressive disorder.